Multiple myeloma therapy, which primarily included IMiDs, proteasome inhibitors, and ASCT, led to a significant increase in CH prevalence that was mainly driven by DNMT3A clonal expansion. Here, DNMT3A is linked to cyclic hematopoiesis.